SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Roche tower in Basel, Switzerland
Approvals
Roche Gains PD-1 Edge on Merck With FDA Nod for Subcutaneous Tecentriq
Tecentriq Hybreza, which combines Roche’s Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology, is being touted as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
September 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art to depict schizophrenia and split personality disorder
Neuropsychiatric disorders
Neurocrine Scraps Schizophrenia Candidate After Phase II Failure
BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about Neurocrine Biosciences’ developmental efforts moving forward.
September 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Infectious disease
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for lenacapavir as a pre-exposure prophylactic option for human immunodeficiency virus.
September 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Astellas' headquarters for the Americas
FDA
Astellas’ Hot Flash Drug Veozah Slapped With Another FDA Warning for Liver Injury
One patient developed elevated liver blood tests after receiving Astellas Pharma’s non-hormonal small molecule blocker, leading the regulator to add a warning to the drug’s label.
September 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Approvals
J&J Positions Tremfya as Stelara Successor With FDA Nod for Ulcerative Colitis
Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.
September 12, 2024
 · 
2 min read
 · 
Tristan Manalac
This illustration is AI10 EPS contains a transparency blend and partial blur effect, which makes up the reflective/highlight shape for the icon.
Business
BridgeBio Grows Up, Trims Pipeline as It Leans Into Late-Stage Assets
As it nears a crucial FDA action date for its transthyretin amyloid cardiomyopathy candidate, BridgeBio focuses on its late-stage pipeline.
September 12, 2024
 · 
4 min read
 · 
Heather McKenzie
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Deals
Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal
Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.
September 12, 2024
 · 
1 min read
 · 
Annalee Armstrong
Pictured: FDA signage at its office in Washington, DC
Adcomms
Intercept’s Ocaliva in Jeopardy as FDA Questions Efficacy, Safety Ahead of Adcomm
With a Friday advisory committee meeting looming, the sole indication for Intercept Pharmaceuticals’ Ocaliva appears to be at risk as the regulator flags issues regarding its post-marketing results.
September 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Pipeline
Moderna Slashes Annual R&D Budget by $1.1B, Eyes 10 Approvals Through 2027
In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending, while pushing back its target for breaking even by two years to 2028.
September 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS